RIÑÓN Y ENFERMEDAD CARDIOVASCULAR - Seden

BIBLIOGRAFÍA
function better than beta-blockade in the treatment of essential
hypertension. Blood Press 4: 85-90; 1995.
677. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de
Jong PE. Antiproteinuric effect of blood-pressure-lowering
agents: A meta-analysis of comparative trials. Nephrol Dial
Transplant 10:1963-1974; 1995.
678. Kashirsagar AV, Joy MS, Hogan SL, Falk RJ, Colindres RE.
Effect of ACE inhibitors in diabetic and nondiabetic chronic
renal disease: A systematic overview of randomised placebocontrolled
trials. Am J Kidney Dis 35: 695-707; 2000.
679. Parving HH, Hovind P. Microalbuminuria in type 1 and type
2 diabetes mellitus: evidence with angiotensin converting
enzyme inhibitors and angiotensin II receptor blockers for
treating early and preventing clinical nephropathy. Curr
Hypertens Rep 4:387-393; 2002.
680. Parving HH, Andersen S, Jacobsen P, Christensen PK,
Rossing K, Hovind P, y cols. Angiotensin receptor blockers in
diabetic nephropathy: Renal and cardiovascular end points.
Semin Nephrol 24:147-157; 2004.
681. Praga M, Andrade CF, Luño J, Arias M, Poveda R, Mora J, y
cols. Antiproteinuric efficacy of losartan in comparison with
amlodipine in non-diabetic proteinuric renal diseases: a
double-blind, randomized clinical trial. Nephrol Dial
Transplant 18:1806-1813; 2003.
682. Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K,
y cols.; Japanese Losartan Therapy Intended for the Global
Renal Protection in Hypertensive Patients (JLIGHT) Study
Investigators. Interim evidence of the renoprotective effect of
the angiotensin II receptor antagonist losartan versus the calcium
channel blocker amlodipine in patients with chronic kidney
disease and hypertension: a report of the Japanese Losartan
Therapy Intended for Global Renal Protection in Hypertensive
Patients (JLIGHT) Study. Clin Exp Nephrol 7:221-230; 2003.
683. Ellis D, Vats A, Moritz ML, Reitz S, Grosso MJ, Janosky JE.
Long-term antiproteinuric and renoprotective efficacy and
safety of losartan in children with proteinuria. J Pediatr
143:89-97; 2003.
684. Panos J, Michelis MF, DeVita MV, Lavie RH, Wilkes BM.
Combined converting enzyme inhibition and angiotensin
receptor blockade reduce proteinuria greater than converting
enzyme inhibition alone: insights into mechanism. Clin
Nephrol 60:13-21; 2003.
685. Komine N, Khang S, Wead LM, Blantz RC, Gabbai FB. Effect
of combining an ACE inhibitor and an angiotensin II receptor
blocker on plasma and kidney tissue angiotensin II levels.
Am J Kidney Dis 39:159-164; 2002.
686. Agarwal R, Siva S, Dunn SR, Sharma K. Add-on angiotensin
II receptor blockade lowers urinary transforming growth factor-beta
levels. Am J Kidney Dis 39:486-492; 2002.
687. Hollenberg NK, Price DA, Fisher ND, Lansang MC, Perkins
B, Gordon MS, y cols. Glomerular hemodynamics and the
renin-angiotensin system in patients with type 1 diabetes
mellitus. Kidney Int 63:172-178; 2003.
688. Jacobsen P, Andersen S, Jensen BR, Parving HH. Additive
effect of ACE inhibition and angiotensin II receptor blockade
in type I diabetic patients with diabetic nephropathy. J Am
Soc Nephrol 14:992-999; 2003.
689. Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective
effects of adding angiotensin II receptor blocker to
maximal recommended doses of ACE inhibitor in diabetic
nephropathy: a randomized double-blind crossover trial.
Diabetes Care 26:2268-2274; 2003.
690. Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G,
Andreucci M y cols. Coadministration of losartan and enalapril
exerts additive antiproteinuric effect in IgA nephropathy.
Am J Kidney Dis 38: 18-25; 2001.
691. Woo KT, Lau YK, Wong KS, Chiang GS. ACEI/ATRA therapy
decreases proteinuria by improving glomerular permselectivity
in IgA nephritis. Kidney Int 58: 2485-2491; 2000.
692. Ferrari P, Marti HP, Pfister M, Frey FJ. Additive antiproteinuric
effect of combined ACE inhibition and angiotensin II
receptor blockade. J Hypertens 20: 125-130; 2002.
693. Berger ED, Bader BD, Ebert C, Risler T, Erley CM. Reduction
of proteinuria; combined effects of receptor blockade and
low dose angiotensin-converting enzyme inhibition. J
Hypertens 20: 739-743; 2002.
694. Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw
D. Dual renin-angiotensin system blockade at optimal doses
for proteinuria. Kidney Int 62: 1020-1025; 2002.
695. Ruilope LM, Aldigier J, Ponticelli C, Oddou-Stock P, Botteri
F, Mann JF. Safety of the combination of valsartan and benazepril
in patients with chronic renal disease. J Hypertens 18:
89-95; 2000.
696. Segura J, Praga M, Campo C, Rodicio JL, Ruilope LM.
Combination is better than monotherapy with ACE inhibitor
or angiotensin receptor antagonist at recommended doses. J
Renin Angiotensin Aldosterone Syst 4:43-47; 2003.
697. Luño J, Barrio V, Goicoechea MA, González C, García de
Vinuesa S, Gómez F, y cols. Effects of dual blockade of the
renin-angiotensin system in primary proteinuric nephropaties.
Kidney Int 62 (Suppl 82): S47-S52; 2002.
698. Kincaid-Smith P, Fairley K, Packhman D. Randomised controlled
crossover study of the effect on proteinuria and blood
pressure of adding an angiotensin II receptor antagonist to an
angiotensin converting enzyme inhibitor in normotensive
patients with chronic renal disease and proteinuria. Nephrol
Dial Transplant 17: 597-601; 2002.
699. Mangrum AJ, Bakris GL. Angiotensin-converting enzyme
inhibitors and angiotensin receptor blockers in chronic renal
disease: safety issues. Semin Nephrol 24:168-175; 2004.
700. Reardon LC, Macpherson DS. Hyperkalemia in outpatients
using angiotensin-converting enzyme inhibitors. How much
should we worry? Arch Intern Med 158:26-32; 1998.
701. Palmer FB. Managing hyperkalemia caused by inhibitors of
the renin-angiotensin-aldosterone system. N Engl J Med 351:
585-92; 2004.
702. National Institutes of Health, National Institute of Diabetes
and Digestive and Kidney Diseases. US Renal Data System,
USRDS 2000 Annual Data Report. Bethesda, Md: National
Institutes of Health, National Institute of Diabetes and
Digestive and Kidney Diseases: 2000.
703. Foley RN, Changchun W, Collins AJ. Cardiovascular risk factor
profiles and kidney function stage in the United States
general population. The NHANES Study. United States Renal
Data System, Minneapolis Medical Research Foundation,
University of Minnesota Twin Cities. United States Renal
Data System: USRDS 2003.
704. Kasiske BL. Risk factors for accelerated atherosclerosis in
renal transplant recipients. Am J Med 84: 985-992,1998
705. Parfrey PS, Foley RN. The clinical epidemiology of cardiac
disease in chronic renal failure. J Am Soc Nephrol 10: 1606-
1615, 1999
208